Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:20 AM
Ignite Modification Date:
2025-12-25 @ 2:20 AM
NCT ID:
NCT06851234
Eligibility Criteria:
Inclusion Criteria:
* Part 1-head injury dynamics:
1. individuals participating in MMA fights or sparring matches,
2. 18 to 50 years of age,
3. able to complete online cognitive neuropsychology tests.
Part-2-Intervention:
<!-- -->
1. having a witnessed closed head injury during a fight
Exclusion Criteria:
* Part 1-head injury dynamics:
1. having a current or previous spinal cord injury,
2. head injury within past six months,
3. being unable to complete the assessment,
4. been diagnosed with underlying neurodegenerative condition,
5. pre-existing hypopituitary function,
6. Pregnancy.
Part-2-Intervention:
1. has absolute contraindications to OMM (e.g. skull fracture, cervical spine fracture, signs of intracranial bleeding or increased intracranial pressure, cervical dissection, space occupying lesion in the cranium, or stroke),
2. suffered a witnessed loss of consciousness (LOC) for greater than 2 minutes, seizures, intractable vomiting or paralysis at the time of the head injury, Participants won't be referred to their private doctors for additional pituitary hormone testing unless there are clinical signs. The optional referral for growth hormone and other pituitary testing by glucagon stimulation Test at Quest labs will be contraindicated if there is risk of and/or a history of (1) cardiovascular (heart) disease, (2) disease of the blood vessel in your brain, or (3) seizures.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
50 Years
Study:
NCT06851234
Study Brief:
Protocol Section:
NCT06851234